AstraZeneca said Thursday it will seek full regulatory approval – as opposed to fast-track emergency use authorization – from the U.S. before the end of the year.
The study also revealed that Americans are overwhelmingly unaware of new legislation touted by democratic lawmakers as a milestone victory i...
No comments:
Post a Comment